Deficit di crescita - Mieloma multiplo

from Salute e Società · host Marco Caracciolo

1. Presentato il Manifesto sociale sul deficit di crescita per difendere la continuità delle cure e le scelte dei medici 2. L’ultima novità nella terapia del mieloma multiplo è belantamab mafodotin, un farmaco approvato in monoterapia in pazienti fortemente pretrattati. È un coniugato anticorpo-farmaco da utilizzare in pazienti che hanno fallito le terapie precedenti.

Episode metadata supplied by the publisher feed · Published Mar 17, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Deficit di crescita - Mieloma multiplo

0:00 6:06

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Salute e Società?

This episode is 6 minutes long.

When was this Salute e Società episode published?

This episode was published on March 17, 2022.

Can I download this Salute e Società episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!